- Home
- Products
Beyfortus (Nirsevimab)
Beyfortus (Nirsevimab)
- Trade Name: Beyfortus®
- Generic Name: Nirsevimab-alip
- Dosage Form & Strength: Intramuscular injection
- Manufactured By: AstraZeneca and Sanofi
- Route of Administration: Single intramuscular injection into the thigh muscle
BEYFORTUS® (Nirsevimab) is a recombinant human monoclonal antibody that acts as an RSV F protein-directed fusion inhibitor, designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV).
Indications:
- Prevention of RSV lower respiratory tract infection in newborns and infants entering their first RSV season.
- Also indicated for children up to 24 months of age who remain vulnerable to severe RSV infection through their second RSV season.
Dosage:
- 50 mg intramuscular injection for infants weighing less than 5 kg.
- 100 mg intramuscular injection for infants weighing 5 kg or more.
- Administer once before RSV season starts or at birth for infants born during RSV season.
Regulatory Status:
- Approved in the European Union, United Kingdom (November 2022), Canada (April 2023), and United States (July 2023).
Note: Maternal RSV vaccination (RSVpreF) may be recommended during pregnancy, but both maternal vaccination and Beyfortus are not typically needed together in most infants.
The most common side effects include rash, fever, and injection site reactions (redness, swelling, pain).
Rash may occur within 14 days after injection.
Fever and injection site reactions are most commonly observed within 7 days post-injection.
Monitor for any allergic reactions post-administration.
To legally import BEYFORTUS (Nirsevimab-alip) into India via Global Rare Meds, the following documents are required:
Required Documentation:
- Valid prescription from a pediatrician or neonatologist
- Patient’s birth certificate or ID proof
- Diagnostic reports (if applicable)
- Import permit (if applicable)
Availability in India:
Beyfortus is not widely available in India. Global Rare Meds enables named-patient imports to major cities including Mumbai, Delhi, Bengaluru, Hyderabad, Chennai, Pune, Ahmedabad, and more.
📧 Email: info@globalraremeds.com
📞 Call / WhatsApp: +91-99675 15602
Global Rare Meds ensures the safe and compliant delivery of BEYFORTUS (Nirsevimab-alip):
- Sourced from authorized distributors in the USA, Canada, Europe, and Australia
- Dispensed strictly against valid medical prescriptions
- Shipping handled through temperature-controlled logistics from the Ambernath, Thane District fulfillment center
- Pan-India and selected international shipping available
Q1: What is the generic name of Beyfortus?
A: The generic name is Nirsevimab-alip.
Q2: Who manufactures Beyfortus?
A: Beyfortus is jointly developed and manufactured by AstraZeneca and Sanofi.
Q3: What is Beyfortus used for?
A: It is used to prevent serious RSV (Respiratory Syncytial Virus) lower respiratory tract infections in infants and young children.
Q4: How is Beyfortus administered?
A: As a single intramuscular injection in the thigh muscle.
Q5: What dosage is recommended?
A:
- 50 mg for infants weighing less than 5 kg
- 100 mg for infants weighing 5 kg or more
Q6: What are common side effects of Beyfortus?
A: Rash, fever, and injection site reactions like redness, swelling, and tenderness.
Q7: How much does Beyfortus cost in India?
A: The cost may vary. For updated pricing, Call / WhatsApp +91-99675 15602 or email info@globalraremeds.com.
Q8: How should Beyfortus be stored?
A: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
Q9: Can Beyfortus be ordered online in India?
A: Yes. Global Rare Meds facilitates authentic, legal, and regulatory-compliant supply of Beyfortus for Indian patients.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
